Vivo Capital Surplus Fund Viii, L.p. - Net Worth and Insider Trading
Vivo Capital Surplus Fund Viii, L.p. Net Worth
The estimated net worth of Vivo Capital Surplus Fund Viii, L.p. is at least $142,066 dollars as of 2024-06-03. Vivo Capital Surplus Fund Viii, L.p. is the 10% Owner of VYNE Therapeutics Inc and owns about 55,712 shares of VYNE Therapeutics Inc (VYNE) stock worth over $142,066. Details can be seen in Vivo Capital Surplus Fund Viii, L.p.'s Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Vivo Capital Surplus Fund Viii, L.p. has not made any transactions after 2018-01-25 and currently still holds the listed stock(s).
Transaction Summary of Vivo Capital Surplus Fund Viii, L.p.
Vivo Capital Surplus Fund Viii, L.p. Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Vivo Capital Surplus Fund Viii, L.p. owns 7 companies in total, including Aligos Therapeutics Inc (ALGS) , Crinetics Pharmaceuticals Inc (CRNX) , and Kadmon Holdings Inc (KDMN) among others .
Insider Ownership Summary of Vivo Capital Surplus Fund Viii, L.p.
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| ALGS | Aligos Therapeutics Inc | 2020-10-15 | 10 percent owner |
| CRNX | Crinetics Pharmaceuticals Inc | 2020-01-29 | 10 percent owner |
| KDMN | Kadmon Holdings Inc | 2019-01-07 | 10 percent owner |
 | | 2018-01-25 | 10 percent owner |
| | 2021-04-22 | 10 percent owner |
| | 2021-02-04 | 10 percent owner |
| | 2022-08-12 | 10 percent owner |
Vivo Capital Surplus Fund Viii, L.p. Latest Holdings Summary
Vivo Capital Surplus Fund Viii, L.p. currently owns a total of 1 stock. Vivo Capital Surplus Fund Viii, L.p. owns 55,712 shares of VYNE Therapeutics Inc (VYNE) as of January 25, 2018, with a value of $142,066.
Latest Holdings of Vivo Capital Surplus Fund Viii, L.p.
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| VYNE | VYNE Therapeutics Inc | 2018-01-25 | 55,712 | 2.55 | 142,066 |
Holding Weightings of Vivo Capital Surplus Fund Viii, L.p.
Vivo Capital Surplus Fund Viii, L.p. Form 4 Trading Tracker
According to the SEC Form 4 filings, Vivo Capital Surplus Fund Viii, L.p. has made a total of 0 transactions in VYNE Therapeutics Inc (VYNE) over the past 5 years. The most-recent trade in VYNE Therapeutics Inc is the acquisition of 4,085 shares on January 25, 2018, which cost Vivo Capital Surplus Fund Viii, L.p. around $5 Million.
Insider Trading History of Vivo Capital Surplus Fund Viii, L.p.
- 1
Vivo Capital Surplus Fund Viii, L.p. Trading Performance
GuruFocus tracks the stock performance after each of Vivo Capital Surplus Fund Viii, L.p.'s buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Vivo Capital Surplus Fund Viii, L.p. is -72.45%. GuruFocus also compares Vivo Capital Surplus Fund Viii, L.p.'s trading performance to market benchmark return within the same time period. The performance of stocks bought by Vivo Capital Surplus Fund Viii, L.p. within 3 months outperforms 0 times out of 1 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Vivo Capital Surplus Fund Viii, L.p.'s insider trading performs compared to the benchmark.
Performance of Vivo Capital Surplus Fund Viii, L.p.
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 20.97 | | | | | |
| Relative Return to S&P 500(%) | 24.21 | | | | | |
Vivo Capital Surplus Fund Viii, L.p. Ownership Network
Vivo Capital Surplus Fund Viii, L.p. Owned Company Details
What does Aligos Therapeutics Inc do?
Who are the key executives at Aligos Therapeutics Inc?
Vivo Capital Surplus Fund Viii, L.p. is the 10 percent owner of Aligos Therapeutics Inc. Other key executives at Aligos Therapeutics Inc include 10 percent owner Roche Holding Ltd , 10 percent owner Roche Finance Ltd , and Chief Medical Officer Matthew W. Mcclure .
Aligos Therapeutics Inc (ALGS) Insider Trades Summary
Over the past 18 months, Vivo Capital Surplus Fund Viii, L.p. made no insider transaction in Aligos Therapeutics Inc (ALGS). Other recent insider transactions involving Aligos Therapeutics Inc (ALGS) include a net purchase of 7,933,601 shares made by Carole Nuechterlein ,
In summary, during the past 3 months, insiders sold 0 shares of Aligos Therapeutics Inc (ALGS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Aligos Therapeutics Inc (ALGS) were sold and 7,933,601 shares were bought by its insiders, resulting in a net purchase of 7,933,601 shares.
Aligos Therapeutics Inc (ALGS)'s detailed insider trading history can be found in Insider Trading Tracker table.
Aligos Therapeutics Inc Insider Transactions
Vivo Capital Surplus Fund Viii, L.p. Mailing Address
Above is the net worth, insider trading, and ownership report for Vivo Capital Surplus Fund Viii, L.p.. You might contact Vivo Capital Surplus Fund Viii, L.p. via mailing address: 505 Hamilton Avenue, Suite 200, Palo Alto Ca 94301.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
